← Leaderboards
Joseph James Shatzel
Oregon Health & Science University
$1,526,714
Attributed
$1,526,714
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $307.9K · FY2020–24$500K$375K$250K$125K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$1,526,714 · 1
By mechanism
R01$1,526,714 · 1
Top collaborators
No co-investigators on record.
Most similar at Oregon Health & Science University
Same institution · by research overlap
- Owen J McCarty$13,437,961
- Monica T Hinds$9,084,363
- Rick Mathews$212,958
- Jevgenia Zilberman-Rudenko$161,420
- Joseph E Aslan$2,927,526
Others in their field
Other Emerging Leaders on “Effective Therapy”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$69,114,853
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$56,084,949
- Yunda Huang · Fred Hutchinson Cancer Center$51,679,442
Research focus
Effective TherapyAntiplatelet DrugsDruggable TargetBenefits And RisksBindingBloodAnticoagulantsBlood Coagulation FactorBlood VesselsBradykininCaringCathetersCessation Of LifeChargeBlood CoagulationAnticoagulationClinical DevelopmentClinical TrialsCoagulation ProcessCytokineDesignDevice Or Instrument DevelopmentDevicesEnrollment
Grant awards (5)
Evaluating the Safety and Efficacy of Targeting the Contact Pathway to Prevent Device Associated Thrombosis.$297,000
R01 · FY2024 · HL · contact PI
Evaluating the Safety and Efficacy of Targeting the Contact Pathway to Prevent Device Associated Thrombosis.$307,853
R01 · FY2023 · HL · contact PI
Evaluating the Safety and Efficacy of Targeting the Contact Pathway to Prevent Device Associated Thrombosis.$307,564
R01 · FY2022 · HL · contact PI
Evaluating the Safety and Efficacy of Targeting the Contact Pathway to Prevent Device Associated Thrombosis.$307,284
R01 · FY2021 · HL · contact PI
Evaluating the Safety and Efficacy of Targeting the Contact Pathway to Prevent Device Associated Thrombosis.$307,013
R01 · FY2020 · HL · contact PI